Iovance Biotherapeutics, Inc.IOVANASDAQ
LOADING
|||
Cash Flow Under Pressure
Below historical average, strong compound growth.
Left:
||||
Operating cash flow minus capital expenditures
Latest
$-364.05M
↓ 84% below average
Average (9y)
$-198.05M
Historical baseline
Range
High:$-19.52M
Low:$-384.11M
CAGR
+38.4%
Consistent expansion
| Period | Value | Change |
|---|---|---|
| 2024 | $-364.05M | +5.2% |
| 2023 | $-384.11M | -22.6% |
| 2022 | $-313.18M | -18.0% |
| 2021 | $-265.51M | -5.4% |
| 2020 | $-251.93M | -51.9% |
| 2019 | $-165.81M | -61.8% |
| 2018 | $-102.45M | -28.5% |
| 2017 | $-79.74M | -133.2% |
| 2016 | $-34.19M | -75.1% |
| 2015 | $-19.52M | - |